Have a feature idea you'd love to see implemented?
Let us know!
ONCT Oncternal Therapeutics Inc
Price (delayed)
$1.16
Market cap
$3.43M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$11.61
Enterprise value
-$9.45M
Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on
Highlights
Oncternal Therapeutics's debt has decreased by 44% YoY and by 19% from the previous quarter
The EPS is up by 19% year-on-year and by 4% since the previous quarter
ONCT's equity has plunged by 75% YoY and by 42% from the previous quarter
The quick ratio has plunged by 71% YoY and by 15% from the previous quarter
Key stats
What are the main financial stats of ONCT
Market
Valuations
Earnings
Shares outstanding
2.96M
Market cap
$3.43M
Enterprise value
-$9.45M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.38
Price to sales (P/S)
1.59
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-4.38
Revenue
$2.16M
EBIT
-$34.58M
EBITDA
-$34.45M
Free cash flow
-$26.63M
Per share
Balance sheet
Liquidity
EPS
-$11.61
Free cash flow per share
-$9
Book value per share
$3.09
Revenue per share
$0.73
TBVPS
$5.27
Total assets
$15.6M
Total liabilities
$6.45M
Debt
$191,000
Equity
$9.15M
Working capital
$8.99M
Debt to equity
0.02
Current ratio
2.39
Quick ratio
2.26
Net debt/EBITDA
0.37
Margins
Efficiency
Dividend
EBITDA margin
-1,594%
Gross margin
100%
Net margin
-1,600%
Operating margin
-1,664%
Return on assets
-131.3%
Return on equity
-177.6%
Return on invested capital
-288.3%
Return on capital employed
-378%
Return on sales
-1,600%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ONCT stock price
How has the Oncternal Therapeutics stock price performed over time
Intraday
1.75%
1 week
4.5%
1 month
-44.5%
1 year
-83.89%
YTD
-89.18%
QTD
-12.12%
Financial performance
How have Oncternal Therapeutics's revenue and profit performed over time
Revenue
$2.16M
Gross profit
$2.16M
Operating income
-$35.96M
Net income
-$34.58M
Gross margin
100%
Net margin
-1,600%
The operating margin has surged by 75% year-on-year and by 18% since the previous quarter
Oncternal Therapeutics's net margin has soared by 75% YoY and by 18% from the previous quarter
Oncternal Therapeutics's operating income has increased by 18% YoY and by 4.5% QoQ
ONCT's revenue is up by 17% since the previous quarter
Growth
What is Oncternal Therapeutics's growth rate over time
Valuation
What is Oncternal Therapeutics stock price valuation
P/E
N/A
P/B
0.38
P/S
1.59
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-4.38
The EPS is up by 19% year-on-year and by 4% since the previous quarter
ONCT's price to book (P/B) is 78% less than its 5-year quarterly average of 1.7 and 62% less than its last 4 quarters average of 1.0
ONCT's equity has plunged by 75% YoY and by 42% from the previous quarter
ONCT's price to sales (P/S) is 95% lower than its 5-year quarterly average of 30.3 and 92% lower than its last 4 quarters average of 19.3
ONCT's revenue is up by 17% since the previous quarter
Efficiency
How efficient is Oncternal Therapeutics business performance
ONCT's return on equity has dropped by 108% year-on-year and by 30% since the previous quarter
The return on invested capital has dropped by 106% year-on-year and by 51% since the previous quarter
The return on sales has surged by 75% year-on-year and by 18% since the previous quarter
The return on assets has dropped by 74% year-on-year and by 21% since the previous quarter
Dividends
What is ONCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ONCT.
Financial health
How did Oncternal Therapeutics financials performed over time
The company's total assets is 142% higher than its total liabilities
The current ratio has plunged by 71% YoY and by 17% from the previous quarter
The quick ratio has plunged by 71% YoY and by 15% from the previous quarter
Oncternal Therapeutics's debt is 98% less than its equity
The debt to equity has soared by 100% since the previous quarter and by 100% year-on-year
ONCT's equity has plunged by 75% YoY and by 42% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.